Edwards Lifesciences Corporation filed a Form 8-K on November 19, 2026, disclosing that it entered into an Amended and Restated Five Year Credit Agreement providing a $750 million multi-currency unsecured revolving credit facility, with Bank of America, N.A. serving as Administrative Agent.

Key Highlights

  • Facility size: The new revolving credit facility provides for $750 million in multi-currency unsecured borrowing capacity.
  • Maturity date: The Credit Agreement matures November 19, 2031, five years from the date of execution.
  • Expansion option: Subject to lender agreement, the Company may increase available capacity by up to an additional $375 million in the aggregate.
  • Interest rate: U.S. dollar-denominated borrowings bear interest at a variable rate based on SOFR or base rate, plus an applicable margin tied to the Company's leverage ratio or debt ratings.
  • Prior facility replaced: The agreement amends and restates the existing Five Year Credit Agreement dated July 15, 2022, with Bank of America, N.A. as Administrative Agent.
  • No amounts drawn: As of the filing date, no amounts had been borrowed under the new Credit Agreement.
  • Signing officer: The filing was signed by Theodora Mistras, Chief Financial Officer.

Edwards Lifesciences Refreshes Bank Credit Facility with Five-Year $750M Agreement

According to the filing, Edwards Lifesciences Corporation (NYSE:EW) entered into the Amended and Restated Five Year Credit Agreement on November 19, 2026, as part of what the company described as "a planned refreshment of its bank credit facility." The agreement replaces the 2022 Credit Agreement and, per the filing, "features improved terms and an extended maturity date compared to the 2022 Credit Agreement." Bank of America, N.A. continues in its role as Administrative Agent.

The Credit Agreement establishes a five-year, $750 million multi-currency unsecured revolving credit facility. The company disclosed that all committed pro rata U.S. dollar-denominated borrowings will bear interest at a variable rate based on the Secured Overnight Financing Rate as administered by the Federal Reserve Bank of New York, or base rate at the Company's election, plus an applicable margin determined by the Company's leverage ratio or debt ratings. The facility also includes an accordion feature allowing the Company to increase total availability by up to $375 million in the aggregate, subject to lender agreement and certain terms and conditions.

The filing states that the Credit Agreement contains "customary representations, warranties, covenants, events of default, terms and conditions, including limitations on liens, incurrence of debt, mergers and significant asset dispositions," and that the Company must comply with a maximum leverage ratio. The company disclosed that the occurrence of an event of default "could result in all loans and other obligations being declared due and payable and the Credit Agreement being terminated." The company stated it expects to use any borrowings for general corporate purposes, and confirmed that no amounts had been borrowed as of the filing date. The company also noted that it and its affiliates from time to time engage certain lenders to provide banking and financial services, and that "all of these engagements are negotiated at arm's length."

What Was Disclosed

Edwards Lifesciences filed an 8-K on November 19, 2026, reporting the execution of an amended and restated $750 million unsecured revolving credit facility maturing November 19, 2031, replacing a 2022 agreement, with no amounts drawn at the time of filing.